Johnson & Johnson Executive Vice President and CFO Joseph Wolk discusses the company’s performance and President Donald Trump’s healthcare agenda on ‘The Claman Countdown.’
Botox and the GLP-1 drug Trulicity are among the latest group of prescription drugs subject to price controls by Medicare.
The Centers for Medicare & Medicaid Services (CMS), the federal agency that runs Medicare, has selected 15 high-cost prescription drugs for government price negotiations. This is the first time the list includes drugs administered in doctors’ offices, not just medications that patients pick up at a pharmacy.
Negotiations with participating drug companies will take place in 2026, and any negotiated or renegotiated prices will go into effect in January 2028. Drug companies can technically choose not to participate in negotiations. However, companies that refuse face a steep federal excise…




